
Sign up to save your podcasts
Or
The shape-shifting telehealth company has spent the past year trying to cash in on GLP-1s, the hottest drug to hit weight loss in decades. It could all slip away. By Madison Muller and Devin Leonard
See omnystudio.com/listener for privacy information.
4.3
44 ratings
The shape-shifting telehealth company has spent the past year trying to cash in on GLP-1s, the hottest drug to hit weight loss in decades. It could all slip away. By Madison Muller and Devin Leonard
See omnystudio.com/listener for privacy information.
1,634 Listeners
1,701 Listeners
407 Listeners
415 Listeners
2,172 Listeners
965 Listeners
1,449 Listeners
192 Listeners
6,043 Listeners
69 Listeners
31 Listeners
57 Listeners
156 Listeners
56 Listeners
2 Listeners
61 Listeners
7 Listeners
218 Listeners
12 Listeners
232 Listeners
20 Listeners
60 Listeners
143 Listeners
148 Listeners
83 Listeners
382 Listeners
21 Listeners
78 Listeners